| Literature DB >> 32296300 |
Vignayanandam Ravindernath Muddapu1, S Akila Parvathy Dharshini2, V Srinivasa Chakravarthy1, M Michael Gromiha2.
Abstract
Neurodegenerative diseases, including Alzheimer, Parkinson, Huntington, and amyotrophic lateral sclerosis, are a prominent class of neurological diseases currently without a cure. They are characterized by an inexorable loss of a specific type of neurons. The selective vulnerability of specific neuronal clusters (typically a subcortical cluster) in the early stages, followed by the spread of the disease to higher cortical areas, is a typical pattern of disease progression. Neurodegenerative diseases share a range of molecular and cellular pathologies, including protein aggregation, mitochondrial dysfunction, glutamate toxicity, calcium load, proteolytic stress, oxidative stress, neuroinflammation, and aging, which contribute to neuronal death. Efforts to treat these diseases are often limited by the fact that they tend to address any one of the above pathological changes while ignoring others. Lack of clarity regarding a possible root cause that underlies all the above pathologies poses a significant challenge. In search of an integrative theory for neurodegenerative pathology, we hypothesize that metabolic deficiency in certain vulnerable neuronal clusters is the common underlying thread that links many dimensions of the disease. The current review aims to present an outline of such an integrative theory. We present a new perspective of neurodegenerative diseases as metabolic disorders at molecular, cellular, and systems levels. This helps to understand a common underlying mechanism of the many facets of the disease and may lead to more promising disease-modifying therapeutic interventions. Here, we briefly discuss the selective metabolic vulnerability of specific neuronal clusters and also the involvement of glia and vascular dysfunctions. Any failure in satisfaction of the metabolic demand by the neurons triggers a chain of events that precipitate various manifestations of neurodegenerative pathology.Entities:
Keywords: excitotoxicity; glia-vascular integrity; insulin resistance; metabolic deficiency; mitochondrial dysfunction; oxidative stress; protein mishandling; selective vulnerability
Year: 2020 PMID: 32296300 PMCID: PMC7137637 DOI: 10.3389/fnins.2020.00213
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
Summarizing the known pathologies in neurodegenerative diseases (Ilieva et al., 2009; Marambaud et al., 2009; Federico et al., 2012; Johri and Beal, 2012; Ravisankar et al., 2018; Sweeney et al., 2018a; Castelli et al., 2019).
| Pathology | PD | AD | HD | ALS |
| Protein aggregation | α-Synuclein | β-Amyloid, tau | Huntingtin (htt) | Superoxide dismutase 1 (SOD1), FUS, TDP-43, OPTN, UBQLN2 |
| Mitochondrial complexes dysfunction | I, IV, V | I, II, III, IV, V | I, II, III, IV, V | I, II, III, IV, V |
| Proteins affecting mitochondrial function | Tau, α-synuclein, parkin, PINK1, DJ-1, LRRK2, HTRA2 | Amyloid precursor protein, presenilin (PS1, PS2), β-amyloid, tau | htt | SOD1 |
| Factors causing calcium homeostasis dysregulations | NMDAR (slow inactivation), α-synuclein pores, mitochondrial abnormalities, underexpression of calcium-buffering proteins | NMDAR (slow inactivation), β-amyloid pores, mitochondrial abnormalities, underexpression of calcium-buffering proteins | NMDAR (slow inactivation), mitochondrial abnormalities, underexpression of calcium-buffering proteins, over sensitization of InsP3R | AMPAR (no GluR2 subunit), mitochondrial abnormalities, underexpression of calcium-buffering proteins |
| Contributors to oxidative stress | α-Synuclein, mitochondrial dysfunction, impaired neurotrophins | β-amyloid, tau, mitochondrial dysfunction, impaired neurotrophins | α-Synuclein, htt, mitochondrial dysfunction | SOD1, mitochondrial dysfunction |
| Glial impairment | Astrocytes, microglia, oligodendrocytes | Astrocytes, microglia | Astrocytes, microglia | Astrocytes, microglia, oligodendrocytes |
| Vascular dysfunctions | CBF reduction, impaired cerebrovascular reactivity, increased BBB permeability, microbleeds, diminished P-glycoprotein function | CBF reduction, impaired cerebrovascular reactivity, impaired neurovascular coupling, increased BBB permeability, microbleeds, diminished glucose transport, and metabolism, diminished P-glycoprotein function | CBF reduction, increased BBB permeability | CBF reduction, microbleeds |
FDA-approved drugs for different neurodegenerative diseases.
| Pathology | Act as | Effective | Drug(s) |
| PD | Dopamine supplement | Most potent in the case of bradykinesia | Levodopa |
| 3, 4-dihydroxyphenylalanine (DOPA) decarboxylase inhibitor | Improves therapeutic benefits of levodopa | Carbidopa, benserazide | |
| Catechol-o-methyltransferase (COMT) inhibitor | Improves therapeutic benefits of levodopa | Tolcapone, entacapone | |
| Monoamine oxidase (MAO) inhibitor | Improves therapeutic benefits of levodopa | Selegiline, rasagiline | |
| Dopamine agonist | Delayed onset of dyskinesia | Apomorphine (rescue drug), pramipexole | |
| Antagonist of NMDA receptor | Antidyskinetic drug | Amantadine | |
| Anticholinergics drug | Young patients dominated by tremor | Trihexyphenidyl, benztropine | |
| Adenosine antagonist | Antidyskinetic drug | Istradefyline | |
| AD | Acetyl cholinesterase inhibitor | Dementia | Donepezil, rivastigmine, galantamine |
| Antagonist of NMDA receptor | Memantine | ||
| ALS | Antagonist of NMDA receptor | Slow down disease progression | Riluzole |
| Antioxidant | Edaravone | ||
| HD | Antichorea drug | Chorea | Tetrabenazine |
FIGURE 1Selective vulnerable neuronal population in various neurodegenerative disorders. STR, striatum; SNc, substantia nigra pars compacta; CA1, cornu ammonis 1; MN, motor neuron; FF, fast fatigable.
FIGURE 2Glutamate-induced excitotoxicity in various neurodegenerative disorders. SNc, substantia nigra pars compacta; STN, subthalamic nucleus; DA, dopamine; GLU, glutamate; CA1, cornu ammonis 1; CA3, cornu ammonis 3; HC, hippocampus; MSN, medium spiny neuron; PYR, pyramidal neuron; BG, basal ganglia; FF MN, fast fatigable motor neuron; SC, spinal cord.
FIGURE 3The plausible hypothesis for selective neurodegeneration in various neurodegenerative disorders. EAAR, excitatory amino acid receptors; MCU, mitochondrial calcium uniporter; SERCA, sarcoplasmic/endoplasmic reticulum Ca2+-ATPase; EAAT, excitatory amino acid transporters; CBF, cerebral blood flow; Ca2+, calcium; ATP, adenosine triphosphate; ROS, reactive oxygen species. BBB, blood-brain barrier; Cytc, cytochrome c; MTP, mitochondrial transition pore; NMDA, N-methyl-D-aspartate; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; VGLUT, vesicular glutamate transporter.